Legend BiotechLEGN +0.91%73 Days Payable is 40.33 as of Mar. 2026, which is 38% below its 10-year median of 65.55. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.55 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, Legend Biotech ranks worse than 65.44% on this metric.
The historical rank and industry rank for Legend Biotech's Days Payable or its related term are showing as below:
LEGN'
s Days Payable Range Over the Past 10 Years
Min: 52.32 Med: 65.55 Max: 108.15
Current: 55.74
During the past 8 years, Legend Biotech's highest Days Payable was 108.15. The lowest was 52.32. And the median was 65.55.
LEGN's Days Payable is ranked worse than 65.44% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs LEGN: 55.74
Legend Biotech's Days Payable
declined
from Mar. 2025 (61.01) to Mar. 2026 (40.33).
It may suggest that Legend Biotechaccelerated paying its suppliers.
Legend Biotech Days Payable Related Terms
Legend Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Legend Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Legend Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Legend Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Legend Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a Days Payable of 40.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Legend Biotech and its competitors. This is 38% below median its historical median of 65.55. Over the past decade, Legend Biotech's Days Payable has ranged from 52.32 to 108.15. According to the industry distribution chart, Legend Biotech ranks #462 out of 706 companies in the Biotechnology industry, placing it in the top 65.4%.
Is Legend Biotech's Days Payable too high?
Legend Biotech's current Days Payable of 40.33 is 38% below median its 10-year median of 65.55. Over the past 10 years, this metric has ranged from a low of 52.32 to a high of 108.15. The Biotechnology industry median Days Payable is 113.56. Legend Biotech's value of 40.33 is 64.5% below this industry median. Based on the distribution chart, Legend Biotech ranks #462 out of 706 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Days Payable compare to DNTH and XENE?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #462 out of 706 companies for Days Payable. This places Legend Biotech in the lower half of its industry. The industry median Days Payable is 113.56. Legend Biotech's value of 40.33 is 64.5% below this benchmark. Historically, Legend Biotech's own Days Payable has ranged from 52.32 to 108.15 over the past decade. While the company's 10-year median is 65.55 vs. the industry median of 113.56, Legend Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current Days Payable of 40.33 is 64.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Legend Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current Days Payable is 40.33, which is 38% below median its own 10-year median of 65.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.55, compared to a current price of $28.70 — trading 70.9% below its estimated fair value. The current Days Payable is 40.33, which is 38% below median its 10-year median of 65.55 and 64.5% below the Biotechnology industry median of 113.56. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Days Payable is 40.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $28.70 is trading 70.9% below its estimated GF Value™ of $98.55.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
Days Payable: 40.33 (38% below median its 10-year median of 65.55)
GF Value™: $98.55 vs. price of $28.70 (70.9% below fair value)
Industry Position: 64.5% below the Biotechnology median (#462 of 706)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
